Investigational influenza (qNIV) vaccine

The investigational in uenza (qNIV) vaccine is our quadrivalent nanoparticle vaccine candidate, targeting seasonal flu. qNIV is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the in influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.¹

Seasonal influenza is a significant global burden, with up to 650,000 flu-related deaths each year around the world.² Current influenza vaccines have several limitations.³ New vaccines may help address these limitations.

In a successful phase 3 trial in the United States, qNIV met all of its endpoints.¹

• 1

  Genes inserted into insect baculovirus

  Four Influenza Hemagglutinin (HA) genes (H1, H3, B-V, B-Y) are engineered into baculovirus for independent expression.

  
• 2

  Sf9 cells infected

  Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.

  
• 3

  DNA enters Sf9 cell nucleus

  H A DNA is transcribed.

  
• 4

  Sf9 cells produce proteins

  HA proteins are each expressed in their native conformation.

  
• 5

  Nanoparticle formation

  Proteins are harvested. Vaccine nanoparticles assemble as proteins arranged around a Polysorbate 80 (PS80) core.

  
• 6

  Final vaccine

  HA vaccine nanoparticles are mixed with Matrix-M™ adjuvant to create the ready-to-use investigational vaccine.